Screener
TG Therapeutics TGTX Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|
| Amortization of leasehold interest | 91 | 94 |
| Deferred income taxes | 4,572 | — |
| Noncash change in lease liability and right of use asset | 1,014 | 885 |
| Change in fair value of equity investments | (2,761) | 285 |
| Change in fair value of notes payable | 612 | 149 |
| Changes in assets and liabilities: | ||
| Increase in inventory | (80,099) | (42,710) |
| Decrease (increase) in other current assets | 24,234 | (9,887) |
Document
FAQ
- What is TG Therapeutics's net gains (losses) on investments?
- TG Therapeutics (TGTX) reported net gains (losses) on investments of $1.23M in Q2 2026.
- How has TG Therapeutics's net gains (losses) on investments changed year-over-year?
- TG Therapeutics's net gains (losses) on investments increased by 777.9% year-over-year, from -$181K to $1.23M.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about TG Therapeutics's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude